Premium
P2‐172: Transcriptome Profile of Peripheral Blood from Patients with Alzheimer's Disease by Rna‐Seq Analysis
Author(s) -
Hara Norikazu,
Mezaki Naomi,
Miura Takeshi,
Kasuga Kensaku,
Tsukie Tamao,
Miyashita Akinori,
Ikeuchi Takeshi
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.1339
Subject(s) - transcriptome , kegg , gene , rna , disease , gene expression , rna seq , peripheral blood , biology , whole blood , biomarker , gene expression profiling , computational biology , bioinformatics , medicine , genetics , immunology
Background:Olfactory deficits have been clearly observed in MCI and AD subjects. Thus, its potential as a biomarker has been proposed and demonstrated by several recent studies. However, further validations of its sensitivity in detecting early AD and specificity in discriminating other neurodegenerative diseases are necessary with concurrent olfactory tests and standardized clinical cognitive examinations. In addition, these findings have not been validated in the Chinese population where aging population is growing rapidly. The goal of this study is to address these critical issues and to evaluate the use of olfactory test battery based on local population in China. Methods: Sixty-one patients with memory complaints from Neurology Clinic of Drum Tower Hospital were recruited into this study. All the participants underwent a battery of neuropsychological tests for cognitive assessment. Thirty-one subjects and seven subjects were diagnosed with MCI and probable AD, respectively. Twenty-one patients were considered as cognitively normal (CN). Olfactory test battery which included one trial of threshold test and two trials of identification tests were performed by OLFACT-C (Osmic Enterprises, Inc., Cincinnati, Ohio, United States). Two patients with nausea of the odors were excluded in this analysis. Results: Increased olfactory threshold (p1⁄40.030) and decreased ability of odor identification (p1⁄40.000) were observed in the MCI and AD patients compared with the CN (Figure 1). Partial correlation analysis showed that odor identification impairment was correlated with age (p1⁄40.001) and cognitive decline (p1⁄40.000). However, augmented olfactory threshold was correlated with age in CN (p1⁄40.011) based on local population in this study. Olfactory threshold was correlated with odor identification (p1⁄40.000) in Spearman correlation analysis, although, as seen also in the Figure 1, the odor threshold data appear to be more variable than odor identification in all three cohorts. Conclusions: In our Chinese cohort, clear olfactory deficits present in both MCI and AD compared to age-matched cognitively normal (CN) subjects. Increased olfactory threshold and decreased ability of odor identification were correlated with aging and cognitive decline. With further validations in follow-up studies of a larger cohort, olfactory test battery could be a viable clinical marker for AD studies.